Yuyu Pharma Launches Export of COVID-19 Diagnostic Kits

[Asia Economy Reporter Cho Hyun-ui] Yuyu Pharma is partnering with diagnostic kit company SD Biosensor to export COVID-19 diagnostic kits.

On the 18th, Yuyu Pharma announced that it signed a supply contract with SD Biosensor for COVID-19 diagnostic kits using the real-time polymerase chain reaction (RT-PCR) method. SD Biosensor's diagnostic kit received emergency use authorization from the U.S. Food and Drug Administration (FDA) last April.

The COVID-19 diagnostic kit model supplied to Yuyu Pharma is the ‘STANDARD M nCoV Real-Time Detection Kit.’ Using the RT-PCR method, which amplifies specific genetic sequences of COVID-19, samples are collected by swabbing the nasal and oropharyngeal areas with a cotton swab, allowing rapid detection of coronavirus infection.

SD Biosensor is one of six domestic companies that have obtained FDA emergency use authorization for COVID-19 diagnostic kits and one of seven companies approved for emergency use by the Korea Disease Control and Prevention Agency. Since developing the world's first SARS diagnostic reagent in 2003, the company has also developed diagnostic reagents for avian influenza, novel influenza, MERS, Ebola, and Zika viruses.

Yoo Won-sang, CEO of Yuyu Pharma, stated, “We plan to expand sales channels worldwide by leveraging Yuyu Pharma’s global network.”

This content was produced with the assistance of AI translation services.